Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rsRNA-28S antisense oligonucleotide
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
rsRNA-28S antisense oligonucleotide is an experimental **antisense oligonucleotide** reagent designed to inhibit a specific 28S ribosomal RNA-derived small RNA, rsRNA-28S. Based on the cited publication context, it was used as a sequence-specific RNA knockdown tool in prostate cancer models to counter the biologic effects of rsRNA-28S, which was reported to regulate chemoresistance through the PTGIS axis. There is no clear evidence from the provided source that this agent has an established proprietary nonproprietary name, sponsor-backed clinical development program, marketed product identity, or defined pharmaceutical formulation beyond its use as a research oligonucleotide.
- Other names
- rsRNA-28S antisense oligonucleotidersRNA28S antisense oligonucleotidersRNA 28S antisense oligonucleotideantisense oligonucleotide against rsRNA-28S
02
Targets
28S rRNA (28S ribosomal RNA)
Beyond the preview
Go deeper on rsRNA-28S antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rsRNA-28S antisense oligonucleotide.